DR. JONATHAN MATTHEW BARASCH, M.D.
Osteopathic Medicine at 168 St, New York, NY
License number
New York 181132
Category
Osteopathic Medicine
Type
Nephrology
Address
Address
622 W 168Th St, New York, NY 10032
Phone
(212) 305-1592
Personal information
See more information about JONATHAN MATTHEW BARASCH at radaris.comName
Address
Phone
15 W 72Nd St APT 15D, New York, NY 10023
2828 Broadway, New York, NY 10025
New York, NY
15 72Nd St, New York, NY 10023
15 72Nd St, New York, NY 10023
Professional information
Dr. Jonathan M Barasch - MD (Doctor of Medicine)
Hospitals:
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
622 W 168Th St, New York 10032
Columbia University Medical Center NEP
622 W 168Th St, New York 10032
Education:
Medical Schools
Columbia University College Of Physicians and Surgeons
Graduated: 1988
Columbia University College Of Physicians and Surgeons
Graduated: 1988
Diagnosis And Monitoring Of Chronic Renal Disease Using Ngal
US Patent:
2010023, Sep 16, 2010
Filed:
May 21, 2010
Appl. No.:
12/785237
Inventors:
Jonathan Matthew BARASCH - New York City NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
International Classification:
A61B 5/00
US Classification:
600573
Abstract:
A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Detection Of Ngal In Chronic Renal Disease
US Patent:
2014008, Mar 20, 2014
Filed:
Nov 25, 2013
Appl. No.:
14/088638
Inventors:
Jonathan M. Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kyoto, JP
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kyoto, JP
International Classification:
G01N 33/68
US Classification:
435 792, 436501
Abstract:
Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Diagnosis And Monitoring Of Chronic Renal Disease Using Ngal
US Patent:
2008001, Jan 17, 2008
Filed:
Jun 28, 2007
Appl. No.:
11/770214
Inventors:
Jonathan BARASCH - New York City NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
Prasad Devarajan - Cincinnati OH, US
Thomas Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
International Classification:
G01N 33/48
US Classification:
436063000
Abstract:
A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Detection Of Ngal In Chronic Renal Disease
US Patent:
2010001, Jan 21, 2010
Filed:
Sep 28, 2009
Appl. No.:
12/567860
Inventors:
Jonathan Matthew Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
International Classification:
G01N 33/53
US Classification:
435 792, 435 71
Abstract:
Methods of assessing the ongoing kidney status in a subject afflicted with chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in fluid samples over time is disclosed. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine and serum as a result of chronic renal tubule cell injury. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Diagnosis And Monitoring Of Chronic Renal Disease Using Ngal
US Patent:
2011014, Jun 16, 2011
Filed:
Feb 11, 2011
Appl. No.:
13/025272
Inventors:
Jonathan Matthew Barasch - New York City NY, US
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
Prasad Devarajan - Cincinnati OH, US
Thomas L. Nickolas - Brooklyn NY, US
Kiyoshi Mori - Kita-ku, JP
International Classification:
G01N 33/53
US Classification:
435 792
Abstract:
A method of assessing the ongoing kidney status of a mammal afflicted with or at risk of developing chronic renal injury or disease, including chronic renal failure (CRF) by detecting the quantity of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in urine, serum or plasma samples at discrete time periods, as well as over time. Incremental increases in NGAL levels in CRF patients over a prolonged period of time are diagnostic of worsening kidney disease. This increase in NGAL precedes and correlates with other indicators of worsening chronic renal disease or CRF, such as increased serum creatinine, increased urine protein secretion, and lower glomerular filtration rate (GFR). Proper detection of worsening (or improving, if treatment has been instituted) renal status over time, confirmed by pre- and post-treatment NGAL levels in the patient, can aid the clinical practitioner in designing and/or maintaining a proper treatment regimen to slow or stop the progression of CRF.
Ngal For Diagnosis Of Renal Conditions
US Patent:
2012021, Aug 30, 2012
Filed:
Jan 27, 2012
Appl. No.:
13/359772
Inventors:
Prasad Devarajan - Cincinnati OH, US
Jonathan M. BARASCH - New York NY, US
Jonathan M. BARASCH - New York NY, US
International Classification:
G01N 33/566, C12Q 1/68
US Classification:
435 612, 436501, 435 792, 422 69, 4352872
Abstract:
Use of serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker, alone or in conjunction with creatinine to aid in the diagnosis of renal conditions such as acute tubular necrosis and acute renal failure, and a method and a kit for assigning a diagnosis of acute tubular necrosis or acute renal failure to a subject based on the correlation between the levels of NGAL and optionally creatinine in a sample obtained from a subject when compared to a sample obtained from a normal subject not experiencing acute tubular necrosis or acute renal failure.
Ngal For Reduction And Amelioration Of Ischemic And Nephrotoxic Injuries
US Patent:
7776824, Aug 17, 2010
Filed:
May 6, 2005
Appl. No.:
11/123364
Inventors:
Jonathan M. Barasch - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Kiyoshi Mori - New York NY, US
Prasad Devarajan - Cincinnati OH, US
Kiyoshi Mori - New York NY, US
Assignee:
The Trustees of Columbia University - New York NY
Children's Hospital Medical Center - Cincincati OH
Children's Hospital Medical Center - Cincincati OH
International Classification:
A61K 38/04, A01N 1/00, A01N 1/02
US Classification:
514 12, 435 11
Abstract:
Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient.
Method For The Early Detection Of Renal Injury
US Patent:
2010002, Feb 4, 2010
Filed:
Sep 25, 2009
Appl. No.:
12/567058
Inventors:
Prasad DEVARAJAN - Cincinnati OH, US
Jonathan M. Barasch - New York NY, US
Jonathan M. Barasch - New York NY, US
International Classification:
G01N 33/53
US Classification:
435 792
Abstract:
A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.
Method For The Early Detection Of Renal Injury
US Patent:
2011014, Jun 16, 2011
Filed:
Feb 16, 2011
Appl. No.:
13/028309
Inventors:
Prasad DEVARAJAN - Cincinnati OH, US
Jonathan M. Barasch - New York NY, US
Jonathan M. Barasch - New York NY, US
International Classification:
G01N 33/68, G01N 33/48
US Classification:
436501, 422 681
Abstract:
A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.